$ENZ
ENZO BIOCHEM INC Stock $enz

$enz Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000121390024109311 Filed on December 16, 2024

Income Statement

Concept	2024 Q4
Revenue	$6.213M
YoY Change	-20.41%
Cost Of Revenue	$3.681M
YoY Change	-15.4%
Gross Profit	$2.532M
YoY Change	-26.71%
Gross Profit Margin	40.75%
Selling, General & Admin	$4.882M
YoY Change	-30.33%
% of Gross Profit	192.81%
Research & Development	$562.0K
YoY Change	-33.8%
% of Gross Profit	22.2%
Depreciation & Amortization	$319.0K
YoY Change	18.15%
% of Gross Profit	12.6%
Operating Expenses	$5.444M
YoY Change	-30.7%
Operating Profit	-$3.622M
YoY Change	-33.86%
Interest Expense	$620.0K
YoY Change	-163.46%
% of Operating Profit
Other Income/Expense, Net	$123.0K
YoY Change	-22.15%
Pretax Income	-$3.071M
YoY Change	-45.89%
Income Tax
% Of Pretax Income
Net Earnings	-$3.376M
YoY Change	-48.97%
Net Earnings / Revenue	-54.34%
Basic Earnings Per Share	-$0.07
Diluted Earnings Per Share	-$0.07
COMMON SHARES
Basic Shares Outstanding	52.24M shares
Diluted Shares Outstanding	52.24K shares

Balance Sheet

Concept	2024 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$47.74M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$6.391M
Prepaid Expenses
Receivables	$3.842M
Other Receivables
Total Short-Term Assets	$59.66M
YoY Change	-32.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.50M
YoY Change	-4.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$481.0K
YoY Change	-33.75%
Total Long-Term Assets	$15.63M
YoY Change	-14.57%
TOTAL ASSETS
Total Short-Term Assets	$59.66M
Total Long-Term Assets	$15.63M
Total Assets	$75.29M
YoY Change	-29.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$5.618M
YoY Change	-44.05%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due	$76.00K
YoY Change	1.33%
Total Short-Term Liabilities	$23.40M
YoY Change	-18.88%
LONG-TERM LIABILITIES
Long-Term Debt	$155.0K
YoY Change	-29.22%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$155.0K
YoY Change	-29.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.40M
Total Long-Term Liabilities	$155.0K
Total Liabilities	$27.63M
YoY Change	-13.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$297.8M
YoY Change	8.31%
Common Stock	$521.0K
YoY Change	3.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$47.66M
YoY Change
Total Liabilities & Shareholders Equity	$75.29M
YoY Change	-29.18%

Cashflow Statement

Concept	2024 Q4
OPERATING ACTIVITIES
Net Income	-$3.376M
YoY Change	-48.97%
Depreciation, Depletion And Amortization	$319.0K
YoY Change	18.15%
Cash From Operating Activities	-$8.990M
YoY Change	-32.78%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$4.552M
YoY Change	-1892.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$200.0K
YoY Change	-61.39%
NET CHANGE
Cash From Operating Activities	-$8.990M
Cash From Investing Activities	$4.552M
Cash From Financing Activities	-$200.0K
Net Change In Cash	-$4.636M
YoY Change	-67.27%
FREE CASH FLOW
Cash From Operating Activities	-$8.990M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	141000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	270000	usd
CY2024Q4	us-gaap	Escrow Deposit EscrowDeposit		usd
CY2024Q4	dei	Document Type DocumentType	10-Q
CY2024Q4	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q4	dei	Document Period End Date DocumentPeriodEndDate	2024-10-31
CY2024Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q4	dei	Entity File Number EntityFileNumber	001-09974
CY2024Q4	dei	Entity Registrant Name EntityRegistrantName	ENZO BIOCHEM, INC.
CY2024Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NY
CY2024Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-2866202
CY2024Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	21 Executive Blvd
CY2024Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	Farmingdale
CY2024Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2024Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11735
CY2024Q4	dei	City Area Code CityAreaCode	(631)
CY2024Q4	dei	Local Phone Number LocalPhoneNumber	755-5500
CY2024Q4	dei	Security12b Title Security12bTitle	Common stock $0.01 par value
CY2024Q4	dei	Trading Symbol TradingSymbol	ENZ
CY2024Q4	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2024Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q4	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	52244074	shares
CY2024Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47735000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52371000	usd
CY2024Q3	us-gaap	Escrow Deposit EscrowDeposit	5000000	usd
CY2024Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3842000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3988000	usd
CY2024Q4	us-gaap	Inventory Net InventoryNet	6391000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	6832000	usd
CY2024Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1693000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1840000	usd
CY2024Q4	us-gaap	Assets Current AssetsCurrent	59661000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	70031000	usd
CY2024Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12495000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12367000	usd
CY2024Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2654000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2836000	usd
CY2024Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	481000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	530000	usd
CY2024Q4	us-gaap	Assets Assets	75291000	usd
CY2024Q3	us-gaap	Assets Assets	85764000	usd
CY2024Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1269000	usd
CY2024Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1376000	usd
CY2024Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	5324000	usd
CY2024Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5618000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5714000	usd
CY2024Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	827000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	841000	usd
CY2024Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	76000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	76000	usd
CY2024Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	10283000	usd
CY2024Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	16787000	usd
CY2024Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23397000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	24794000	usd
CY2024Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2209000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2403000	usd
CY2024Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	155000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	189000	usd
CY2024Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	1872000	usd
CY2024Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	2266000	usd
CY2024Q4	us-gaap	Liabilities Liabilities	27633000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	29652000	usd
CY2024Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2024Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52244074	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52244074	shares
CY2024Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52244074	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52244074	shares
CY2024Q4	us-gaap	Common Stock Value CommonStockValue	521000	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	521000	usd
CY2024Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	342981000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	348134000	usd
CY2024Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-297804000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-294428000	usd
CY2024Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1960000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1885000	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	47658000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	56112000	usd
CY2024Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	75291000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	85764000	usd
CY2024Q4	us-gaap	Revenues Revenues	6213000	usd
CY2023Q4	us-gaap	Revenues Revenues	7806000	usd
CY2024Q4	us-gaap	Cost Of Revenue CostOfRevenue	3681000	usd
CY2023Q4	us-gaap	Cost Of Revenue CostOfRevenue	4351000	usd
CY2024Q4	enz	Cost Of Revenue Inventory Provision CostOfRevenueInventoryProvision	252000	usd
CY2024Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	562000	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	849000	usd
CY2024Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4882000	usd
CY2023Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7007000	usd
CY2024Q4	us-gaap	Legal Fees LegalFees	458000	usd
CY2023Q4	us-gaap	Legal Fees LegalFees	1075000	usd
CY2024Q4	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	9835000	usd
CY2023Q4	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	13282000	usd
CY2024Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-3622000	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-5476000	usd
CY2024Q4	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	620000	usd
CY2023Q4	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	977000	usd
CY2023Q4	enz	Change In Fair Value Of Convertible Debentures ChangeInFairValueOfConvertibleDebentures	328000	usd
CY2024Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	123000	usd
CY2023Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	158000	usd
CY2024Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-192000	usd
CY2023Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1006000	usd
CY2024Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3071000	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5675000	usd
CY2024Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3071000	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5675000	usd
CY2024Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-305000	usd
CY2023Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-941000	usd
CY2024Q4	us-gaap	Net Income Loss NetIncomeLoss	-3376000	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-6616000	usd
CY2024Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.07
CY2024Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.07
CY2023Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.11
CY2023Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.11
CY2024Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2024Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2023Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
CY2023Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
CY2024Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2024Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2024Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52244	shares
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50184	shares
CY2024Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52244	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50184	shares
CY2024Q4	us-gaap	Net Income Loss NetIncomeLoss	-3376000	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-6616000	usd
CY2024Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	75000	usd
CY2023Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	868000	usd
CY2024Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3301000	usd
CY2023Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5748000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	56112000	usd
CY2024Q4	us-gaap	Net Income Loss NetIncomeLoss	-3376000	usd
CY2024Q4	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	5324000	usd
CY2024Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	171000	usd
CY2024Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	75000	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	47658000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	78462000	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-6616000	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	485000	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1075000	usd
CY2023Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	868000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	74275000	usd
CY2024Q4	us-gaap	Net Income Loss NetIncomeLoss	-3376000	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-6616000	usd
CY2023Q4	enz	Change In Fair Value Of Convertible Debenture ChangeInFairValueOfConvertibleDebenture	328000	usd
CY2024Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	319000	usd
CY2023Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	270000	usd
CY2024Q4	us-gaap	Share Based Compensation ShareBasedCompensation	171000	usd
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	1075000	usd
CY2024Q4	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	109000	usd
CY2023Q4	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	109000	usd
CY2024Q4	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-165000	usd
CY2023Q4	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-970000	usd
CY2024Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17000	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2019000	usd
CY2024Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-277000	usd
CY2023Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-428000	usd
CY2024Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-469000	usd
CY2023Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-346000	usd
CY2024Q4	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-324000	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-5601000	usd
CY2024Q4	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-6783000	usd
CY2023Q4	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-6702000	usd
CY2024Q4	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-5614000	usd
CY2023Q4	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-6758000	usd
CY2024Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8990000	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13374000	usd
CY2024Q4	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	5000000	usd
CY2024Q4	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	448000	usd
CY2023Q4	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	254000	usd
CY2024Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4552000	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-254000	usd
CY2024Q4	us-gaap	Repayments Of First Mortgage Bond RepaymentsOfFirstMortgageBond	37000	usd
CY2023Q4	us-gaap	Repayments Of First Mortgage Bond RepaymentsOfFirstMortgageBond	51000	usd
CY2024Q4	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	163000	usd
CY2023Q4	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	467000	usd
CY2024Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-200000	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-518000	usd
CY2024Q4	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2000	usd
CY2023Q4	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-20000	usd
CY2024Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4636000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14166000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52371000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83373000	usd
CY2024Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47735000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69207000	usd
CY2024Q4	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q4	us-gaap	Cash Held In Foreign Currency CashHeldInForeignCurrency	186000	usd
CY2024Q3	us-gaap	Cash Held In Foreign Currency CashHeldInForeignCurrency	391000	usd
CY2024Q4	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of Credit Risk</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company believes the fair value of the aforementioned financial instruments approximates the cost due to the immediate or short-term nature of these items. At October 31, 2024 and July 31, 2024, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents or restricted cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concentration of credit risk with respect to the Company’s Products segment is mitigated by the diversity of the Company’s customers and their dispersion across many different geographic regions. To reduce risk, the Company routinely assesses the financial strength of these customers and, consequently, believes that its accounts receivable credit exposure with respect to these customers is limited.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q4	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Reclassifications</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations or discontinued operations.</p>
CY2024Q4	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	250000	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	1437000	usd
CY2024Q4	enz	Disposal Group Including Discontinued Operation Other Expenseincome DisposalGroupIncludingDiscontinuedOperationOtherExpenseincome	-55000	usd
CY2023Q4	enz	Disposal Group Including Discontinued Operation Other Expenseincome DisposalGroupIncludingDiscontinuedOperationOtherExpenseincome	496000	usd
CY2024Q4	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-305000	usd
CY2023Q4	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-941000	usd
CY2024Q4	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	6842000	usd
CY2023Q4	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	8082000	usd
CY2024Q4	us-gaap	Shares Outstanding SharesOutstanding	2125000	shares
CY2024Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	35000	shares
CY2023Q4	us-gaap	Shares Outstanding SharesOutstanding	3320000	shares
CY2023Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	54000	shares
CY2024Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	1199000	shares
CY2024Q4	us-gaap	Revenues Revenues	6213000	usd
CY2023Q4	us-gaap	Revenues Revenues	7806000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3988000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4808000	usd
CY2024Q4	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
CY2023Q4	us-gaap	Interest Paid Net InterestPaidNet	92000	usd
CY2024Q3	us-gaap	Escrow Deposit EscrowDeposit	5000000	usd
CY2024Q4	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	163000	usd
CY2023Q4	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	467000	usd
CY2024Q4	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.1
CY2024Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	5324000	usd
CY2024Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1482000	usd
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1794000	usd
CY2024Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2386000	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2461000	usd
CY2024Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2523000	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2577000	usd
CY2024Q4	us-gaap	Inventory Net InventoryNet	6391000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	6832000	usd
CY2023Q2	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	7608000	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1000000	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.31
CY2023Q2	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	7000000	usd
CY2023Q4	enz	Change In Fair Value Of Convertible Debentures ChangeInFairValueOfConvertibleDebentures	328000	usd
CY2023Q1	enz	Prepay Outstanding Principal Amount PrepayOutstandingPrincipalAmount	4000000	usd
CY2024Q2	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	3609000	usd
CY2023Q2	enz	Warrants Exercisable Term WarrantsExercisableTerm	P5Y
CY2020Q2	enz	Foreign Exchange Rate Amount ForeignExchangeRateAmount	400000	chf
CY2020Q3	enz	Foreign Exchange Rate Amount ForeignExchangeRateAmount	400000	usd
CY2020Q2	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0	pure
CY2024Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	39000	usd
CY2024Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	77000	usd
CY2024Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	77000	usd
CY2024Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	38000	usd
CY2024Q4	us-gaap	Long Term Debt LongTermDebt	231000	usd
CY2024Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	76000	usd
CY2024Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	155000	usd
CY2024Q4	enz	Lease Option To Extend LeaseOptionToExtend	P3Y
CY2024Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2654000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2836000	usd
CY2024Q4	enz	Lease Rightof Use Asset LeaseRightofUseAsset	2654000	usd
CY2024Q3	enz	Lease Rightof Use Asset LeaseRightofUseAsset	2836000	usd
CY2024Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	827000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	841000	usd
CY2024Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2209000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2403000	usd
CY2024Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3036000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3244000	usd
CY2024Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	95000	usd
CY2024Q4	us-gaap	Sublease Income SubleaseIncome	126000	usd
CY2023Q4	us-gaap	Sublease Income SubleaseIncome	126000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	731000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	886000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	881000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	808000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3306000	usd
CY2024Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3036000	usd
CY2024Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y6M
CY2024Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.051	pure
CY2024Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	3197000	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	3459000	usd
CY2024Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	434000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	405000	usd
CY2024Q4	enz	Accrued Legal Liabilities Current AccruedLegalLiabilitiesCurrent	1472000	usd
CY2024Q3	enz	Accrued Legal Liabilities Current AccruedLegalLiabilitiesCurrent	1235000	usd
CY2024Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	515000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	615000	usd
CY2024Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5618000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5714000	usd
CY2024Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	158000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	114000	usd
CY2024Q4	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.1
CY2024Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	5324000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	enz	Aggregate Offering Prices AggregateOfferingPrices	30000000	usd
CY2023Q2	enz	Aggregate Gross Proceeds Percentage AggregateGrossProceedsPercentage	0.03	pure
CY2023	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	150000000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	4000000	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4698000	shares
CY2024Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	171000	usd
CY2023Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1075000	usd
CY2024Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	171000	usd
CY2023Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1075000	usd
CY2024Q4	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2136870	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.31
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5000	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.11
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1500	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.32
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2140370	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.31
CY2024Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y4M24D
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1372037	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.44
CY2024Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P1Y4M24D
CY2024Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	359000	usd
CY2024	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2024Q4	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 13 – Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Ransomware Attack</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2023, the Company experienced a ransomware attack (the “ransomware attack”) that impacted certain critical information technology systems, principally of the discontinued operations. The Company later became aware that certain data, including names, test information, and Social Security numbers, was accessed, and in some instances, exfiltrated from the Company’s information technology systems as part of this incident. The investigation identified unauthorized access to or acquisition of clinical test information of approximately 2,470,000 individuals. The Social Security numbers of approximately 600,000 of these individuals may also have been involved. Additionally, the Company determined that some employees’ information may have been involved. The Company provided notice to the individuals whose information may have been involved, as well as to regulatory authorities, in accordance with applicable law.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the ransomware attack, Enzo was subject to regulatory inquiry from the New York Attorney General, a joint inquiry from the Connecticut and New Jersey Attorneys General and an inquiry from the Utah Attorney General. All inquiries asked questions about the ransomware attack, as well as the corrective actions taken in response. The Company responded to all such inquiries, and there have been no further inquiries from the Utah Attorney General. The matters with the New York, Connecticut and New Jersey Attorneys General are now closed, as they were resolved by agreements with each of the three states effective August 8, 2024. A provision was recorded in the consolidated financial statements as of July 31, 2024 based on the settlement terms of the agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Enzo was also subject to regulatory inquiries from the U.S. Department of Health and Human Services Office for Civil Rights (the “Office for Civil Rights”) regarding the ransomware attack. The Company has responded to all requests. It is not known at this time whether the Office for Civil Rights will seek a penalty against the Company. We are unable to evaluate the likelihood of an outcome, favorable or unfavorable, to the Company or to estimate the amount or range of any potential liability, if any, at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There is also pending class action litigation:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>In re Enzo Biochem Data Breach Litigation</i>, No. 2:23-cv-04282 (EDNY)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the Eastern District of New York (“EDNY”), twenty putative class actions were consolidated alleging various harms stemming from the April 2023 data incident. Lead counsel was appointed and filed a Consolidated Amended Complaint on November 13, 2023. The complaint sought to certify a federal class as well as several state subclasses. The Consolidated Amended Complaint brings various statutory and common law claims, including negligence, negligence per se, breach of fiduciary duty, breach of implied contract, breach of the implied covenant of good faith and fair dealing, violation of the New York’s General Business Law § 349, Invasion of Privacy, violations of the Connecticut Unfair Trade Practices Act, and violations of the New Jersey Consumer Fraud Act. An agreement in principle to settle the case has been reached. The Company expects to have the agreement formalized before the end of the 2024 calendar year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Maria Sgambati et al., v. Enzo Biochem, Inc., et al</i>., Index No. 619511/2023 (N.Y. Sup. Ct.)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This is a putative class action pending in state court alleging various harms stemming from the April 2023 data incident. The complaint seeks to certify a class of New York residents. The complaint brings claims of negligence; negligence <i>per se</i>; breach of implied covenant and good faith and fair dealing; breach of duty; breach of implied contract; and violations of New York’s Deceptive Acts and Practices § 349. The Company has filed a motion to stay this action pending the resolution of the EDNY Federal Action, and the motion was granted by the court. The Company anticipates that the case will be dismissed once the settlement in the federal case receives final approval from the court, likely sometime in 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Louis v. Enzo Biochem, Inc. et al.</i>, Index No. 653281/2023 (N.Y. Sup. Ct.)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This is a putative class action pending in state court alleging various harms stemming from the April 2023 data incident. The complaint seeks to certify a class of New York citizens. The complaint brings claims of negligence; negligence <i>per se</i>; breach of duty; breach of implied contract; breach of implied covenant of good faith and fair dealing; and violations of New York’s Deceptive Acts and Practices § 349. The Company has filed a motion to stay this action pending the resolution of the EDNY Federal Action, and the motion remains pending. The Company anticipates that the case will be dismissed once the settlement in the federal case receives final approval from the court, likely sometime in 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A provision was made in the consolidated financial statements as of July 31, 2023 for the above class action litigation matters based on a reasonable estimate of loss and updated as applicable as of October 31, 2024 and July 31, 2024; however, the actual exposure may differ.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Patent Matters</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company (as plaintiff) has brought cases in the United States District Court for the District of Delaware (“the Court”), alleging patent infringement against various companies. At this time, all of such cases have been resolved, except for one described below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There is currently one case that was originally brought by the Company that is still pending in the Court. In that case, Enzo alleges patent infringement of the ‘197 patent against Becton Dickinson defendants. The claims in that case are stayed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 2, 2021, the U.S. Patent and Trademark Office (“PTO”) issued a non-final office action in an <i>ex parte</i> reexamination concerning the ‘197 Patent. In the office action, the PTO rejected certain claims of the ‘197 Patent under 35 U.S.C. §§ 102 and 103, and for nonstatutory double-patenting. Enzo responded to the office action on January 3, 2022, and the proceeding remains pending. Becton Dickinson requested another <i>ex parte</i> reexamination concerning the ‘197 patent on July 26, 2022. On September 16, 2022, the PTO ordered that <i>ex parte </i>reexamination as to certain claims of the ‘197 patent. Enzo filed a petition to terminate that second reexamination proceeding on November 16, 2022, which was denied on July 26, 2024. The PTO merged the <i>ex parte </i>reexamination proceedings as of August 2, 2024. On September 17, 2024, the PTO issued an office action, rejecting the claims subject to the merged reexamination proceedings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Arbitration with former executives</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company terminated the employment of Elazar Rabbani, Ph.D., the Company’s former Chief Executive Officer, effective April 21, 2022. Dr. Rabbani was a director of the Company until the Annual Meeting on January 31, 2024, when his term expired. Dr. Rabbani was a party to an employment agreement with the Company that entitled him to certain termination benefits, including severance pay, acceleration of vesting of share-based compensation, and continuation of benefits. Based on the terms of his employment agreement, the Company estimated and accrued a charge of $2,600 in fiscal year 2022. The charge was partially offset by the reversal of bonus accruals. In May 2022, the Company paid Dr. Rabbani $2,123 in severance (the payment constituted taxable income, but the Company did not withhold taxes from the payment). In July 2022, the Company paid Dr. Rabbani’s income and other withholding taxes of $1,024 related to that payment on Dr. Rabbani’s behalf. On July 8, 2022, the Company filed a demand for arbitration with the American Arbitration Association (the “AAA”) seeking, among other things, a declaration that the Company had fully satisfied its contractual obligations to Dr. Rabbani and seeking the tax withholding reimbursement referenced above. On August 4, 2022, Dr. Rabbani filed counterclaims in the arbitration seeking, among other things, a bonus for fiscal year 2021 and additional severance that he asserted was owed to him. At the parties’ joint request, the arbitration has been stayed while the parties work towards resolving the matter. A provision was made in the consolidated financial statements as of July 31, 2023 based on a reasonable estimate of loss; however, the actual exposure may differ.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 25, 2022, Barry Weiner, the Company’s co-founder and President, notified the Company that he was terminating his employment as President of the Company for “Good Reason,” as defined in his employment agreement. The Company accepted Mr. Weiner’s termination, effective April 19, 2022, but disagreed with Mr. Weiner’s assertion regarding “Good Reason.” On October 24, 2023, the Company and Mr. Weiner reached an agreement resolving the dispute, and a provision was made in the financial consolidated statements as of July 31, 2023 based on the settlement agreement. The Company paid Mr. Weiner $3,600, less applicable withholding taxes, related to the agreement in November 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other Matters</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On or about March 2, 2023, a Verified Complaint was filed in the Supreme Court of the State of New York, New York County captioned Elazar Rabbani (as plaintiff) v. Mary Tagliaferri, et al. (as defendants), Index No. 651120/2023. The Verified Complaint purports to assert causes of action for breach of fiduciary duty and corporate waste under N.Y.B.C.L. § 720, and seeks an accounting and certain injunctive relief. On August 4, 2023, defendants moved to dismiss all the causes of action asserted in the Verified Complaint. Plaintiff filed an amended complaint on or about October 4, 2023, adding, among other things, an additional cause of action for violation of N.Y.B.C.L. § 626. On October 23, 2023, defendants filed a reply in further support of their motion to dismiss. On November 6, 2023, plaintiff filed an opposition to defendants’ motion to dismiss. On November 17, 2023, defendants filed a reply brief in further support of their motion to dismiss the amended complaint. On or about July 17, 2024, the Court granted, in part, the defendants’ motion to dismiss the amended complaint. On or about August 16, 2024, plaintiff noticed an appeal from the order granting that dismissal. On or about September 18, 2024, plaintiff filed a Verified Second Amended Complaint. On October 11, 2024, the defendants filed a joint stipulation and letter requesting the court to extend the deadline to respond to the Second Amended complaint from October 18, 2024 to November 18, 2024. On November 15, 2024, the plaintiff discontinued the derivative case and the related appeal (without prejudice).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On or about September 26, 2023, James G. Wolf, individually and as the trustee of the Wolf Family Charitable Foundation, Barbaranne R. Wolf, Stephen Paul Wolf, and Preston M. Wolf (collectively the “Petitioners”) initiated an appraisal action against Enzo in the New York Supreme Court for Suffolk County. Petitioners seek an appraisal of the value of their shares in the Company. The amount of damages sought by the Petitioners is unspecified. On or about August 21, 2024, the Court dismissed the Company’s Second and Third Affirmative Defenses. On or about September 19, 2024, the Court granted the Company permission to move for leave to reargue the Court’s dismissal decision. This matter has been fully briefed by the parties. We do not anticipate a decision until sometime in the first quarter of 2025. The Company intends to vigorously litigate both (i) Petitioners’ alleged entitlement to dissenting shareholder appraisal rights and (ii) the correct valuation of Petitioners’ shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In our discontinued Clinical Labs operations, third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments that we received. In April 2024, the Company engaged in settlement negotiations for a government payer and reached a verbal settlement. The settlement was finalized in a formal written settlement agreement on August 14, 2024. The settlement resolved allegations that Enzo Clinical Labs, Inc. overbilled the Connecticut Medicaid program for testing services. The settlement was paid in August 2024 for $1,700 to resolve the State of Connecticut’s allegations and $175 was paid to settle the whistleblowers’ legal fees. On September 18, 2024, we received the unsealed complaint filed by the same whistleblowers in the Southern District of New York (“SDNY”) alleging, among other things, that the Company falsely billed Medicaid and Medicare for COVID-19 tests by utilizing inappropriate diagnostic codes to trigger payments for such tests. The SDNY advised the court that the government was not intervening in the case; however, the private plaintiffs are still pursuing the case on the governments’ behalf. The court has ordered that the matter be stayed until January 15, 2025, so that the parties may explore potential settlement of the matter.</p>
CY2023Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	2470000	shares
CY2023Q2	enz	Number Of Security Shares NumberOfSecurityShares	600000	shares
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	2600000	usd
CY2024Q3	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	1700000	usd
CY2024Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent		usd
CY2023Q4	enz	Cost Of Revenue Inventory Provision CostOfRevenueInventoryProvision		usd
CY2024Q4	enz	Change In Fair Value Of Convertible Debentures ChangeInFairValueOfConvertibleDebentures		usd
CY2023Q4	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024Q4	dei	Amendment Flag AmendmentFlag	false
CY2024Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--07-31
CY2024Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
CY2024Q4	dei	Entity Central Index Key EntityCentralIndexKey	0000316253

Files In Submission

Name	View Source	Status
0001213900-24-109311-index-headers.html	Edgar Link	pending
0001213900-24-109311-index.html	Edgar Link	pending
0001213900-24-109311.txt	Edgar Link	pending
0001213900-24-109311-xbrl.zip	Edgar Link	pending
ea0224507-10q_enzobio.htm	Edgar Link	pending
ea022450701ex31-1_enzobio.htm	Edgar Link	pending
ea022450701ex31-2_enzobio.htm	Edgar Link	pending
ea022450701ex32-1_enzobio.htm	Edgar Link	pending
ea022450701ex32-2_enzobio.htm	Edgar Link	pending
enz-20241031.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
enz-20241031_def.xml	Edgar Link	unprocessable
enz-20241031_lab.xml	Edgar Link	unprocessable
enz-20241031_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0224507-10q_enzobio_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
enz-20241031_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENZ
ENZO BIOCHEM INC Stock $enz

2024 Q4 Form 10-Q Financial Statement

#000121390024109311 Filed on December 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENZ ENZO BIOCHEM INC Stock $enz

2024 Q4 Form 10-Q Financial Statement

#000121390024109311 Filed on December 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENZ
ENZO BIOCHEM INC Stock $enz